Collection

Alpha Therapy

Submission status
Open
Open for submission from
23 August 2023
Submission deadline
Ongoing
Targeted Alpha Therapy is a highly promising approach for treatment of cancer. The innovation of PSMA targeting vectors labelled with Actinium-225, such as 225Ac-PSMA, has impressively demonstrated the great potential of cancer therapy using alpha emitting radionuclides. The development of alpha radiopharmaceuticals addressing further novel targets and utilizing a variety of alpha emitters, is an exciting area of current research. This collection welcomes contributions on preclinical and clinical studies investigating alpha radiopharmaceuticals for application in targeted alpha therapy.

Editors

  • Prof. Dr. Alfred Morgenstern, PhD Prof. Dr. Alfred Morgenstern, PhD  &

    Prof. Dr. Alfred Morgenstern, PhD

    Alfred Morgenstern has obtained his Ph.D. in radiochemistry from Technical University Munich, Germany. He is a senior scientist at the Joint Research Centre of the European Commission in Karlsruhe and an extraordinary professor at the Faculty of Health of University of Pretoria. His main research focus lies in the development of radiopharmaceuticals for application in targeted alpha therapy since 2001. He has published > 210 peer-reviewed journal publications.

  • Prof. Dr. Mike Sathekge, MD Prof. Dr. Mike Sathekge, MD

    Prof. Dr. Mike Sathekge, MD

    Mike Sathekge is a Professor and Head of the South African Nuclear Medicine Research Infrastructure (NuMeRI), Nuclear Medicine at University of Pretoria and Steve Biko Academic Hospital. He has published over 240 peer-reviewed articles, excluding abstracts and book chapters, and one of the global leaders concerning treatment of prostate cancer using targeted alpha therapy. He is he President of the World Association of Radiopharmaceuticals and Molecular Therapy and the Chair of the Africa Health Research Institution, and holds numerous scientific honours and awards.

Articles (7 in this collection)